Written by: Katie Carter, PharmD, BCPS, Indiana University Health
Download Here

Olaparib (Lynparza) is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is currently FDA approved as targeted therapy for BRCA-mutated breast cancer and ovarian cancer.  This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding dose adjustment.
Continue reading Olaparib in BRCA-mutated Breast, Ovarian and Pancreatic Cancer

Read More